Heterogeneity of Randomized Controlled Trials of Fecal Microbiota Transplantation in Recurrent Clostridioides difficile Infection
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-2568
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Heterogeneity of Randomized Controlled Trials of Fecal Microbiota Transplantation in Recurrent Clostridioides difficile Infection ; day:18 ; month:7 ; year:2021 ; pages:1-8
Digestive diseases and sciences ; (18.7.2021), 1-8
- Creator
-
Feuerstadt, Paul
Aroniadis, Olga C.
Svedlund, Felicia L.
Garcia, Mariana
Stong, Laura
Boules, Mena
Khanna, Sahil
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s10620-021-07141-9
- URN
-
urn:nbn:de:101:1-2021102119361953160806
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:20 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Feuerstadt, Paul
- Aroniadis, Olga C.
- Svedlund, Felicia L.
- Garcia, Mariana
- Stong, Laura
- Boules, Mena
- Khanna, Sahil
- SpringerLink (Online service)
Other Objects (12)
Fecal Microbiota Transplantation Is Effective for Postcolectomy Recurrent Clostridioides difficile Infection
Editorial: Rejuvenating the Microbiome in Recurrent Clostridioides difficile Infection with Fecal Microbiota Transplant
Applications of Fecal Microbiota Transplantation: Emphasis on Clostridioides difficile Infections
Budget Impact Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) for Preventing Recurrent Clostridioides difficile Infection in the US
Oral, frozen fecal microbiota transplant (FMT) capsules for recurrent Clostridium difficile infection
Fecal microbiota composition is a better predictor of recurrent Clostridioides difficile infection than clinical factors in a prospective, multicentre cohort study
Microbiota-Based Therapeutics as New Standard-of-Care Treatment for Recurrent Clostridioides difficile Infection
Journal Summary: Microbiome-Based Therapies for Recurrent Clostridioides difficile
Fecal Microbiota Transplantation May Be the Best Option in Treating Multiple Clostridioides difficile Infection: A Network Meta-Analysis
A Multi-Factorial Observational Study on Sequential Fecal Microbiota Transplant in Patients with Medically Refractory Clostridioides difficile Infection
Microbiota-based markers predictive of development of Clostridioides difficile infection
Cost-Effectiveness Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) Versus Standard of Care for the Prevention of Recurrent Clostridioides difficile Infection in the USA
Fecal Microbiota Transplantation Is Effective for Postcolectomy Recurrent Clostridioides difficile Infection
Editorial: Rejuvenating the Microbiome in Recurrent Clostridioides difficile Infection with Fecal Microbiota Transplant
Applications of Fecal Microbiota Transplantation: Emphasis on Clostridioides difficile Infections
Budget Impact Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) for Preventing Recurrent Clostridioides difficile Infection in the US
Oral, frozen fecal microbiota transplant (FMT) capsules for recurrent Clostridium difficile infection
Fecal microbiota composition is a better predictor of recurrent Clostridioides difficile infection than clinical factors in a prospective, multicentre cohort study
Microbiota-Based Therapeutics as New Standard-of-Care Treatment for Recurrent Clostridioides difficile Infection
Journal Summary: Microbiome-Based Therapies for Recurrent Clostridioides difficile
Fecal Microbiota Transplantation May Be the Best Option in Treating Multiple Clostridioides difficile Infection: A Network Meta-Analysis
A Multi-Factorial Observational Study on Sequential Fecal Microbiota Transplant in Patients with Medically Refractory Clostridioides difficile Infection
Microbiota-based markers predictive of development of Clostridioides difficile infection
Cost-Effectiveness Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) Versus Standard of Care for the Prevention of Recurrent Clostridioides difficile Infection in the USA
Fecal Microbiota Transplantation Is Effective for Postcolectomy Recurrent Clostridioides difficile Infection
Editorial: Rejuvenating the Microbiome in Recurrent Clostridioides difficile Infection with Fecal Microbiota Transplant
Applications of Fecal Microbiota Transplantation: Emphasis on Clostridioides difficile Infections
Budget Impact Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) for Preventing Recurrent Clostridioides difficile Infection in the US
Oral, frozen fecal microbiota transplant (FMT) capsules for recurrent Clostridium difficile infection
Fecal microbiota composition is a better predictor of recurrent Clostridioides difficile infection than clinical factors in a prospective, multicentre cohort study
Microbiota-Based Therapeutics as New Standard-of-Care Treatment for Recurrent Clostridioides difficile Infection
Journal Summary: Microbiome-Based Therapies for Recurrent Clostridioides difficile
Fecal Microbiota Transplantation May Be the Best Option in Treating Multiple Clostridioides difficile Infection: A Network Meta-Analysis
A Multi-Factorial Observational Study on Sequential Fecal Microbiota Transplant in Patients with Medically Refractory Clostridioides difficile Infection
Microbiota-based markers predictive of development of Clostridioides difficile infection